Clinical data from trials conducted in the UK or EU may not meet the FDA expectations. Find out why and what to do about it.
The FDA has its own set of concerns and limitations that differ significantly from those in the UK (regulated by the MHRA – Medicines and Healthcare products Regulatory Agency) and the EU (regulated by the EMA – European Medicines Agency and other bodies for medical devices). In the past, the physiological and cultural differences from the US to the rest of the world along with genetic and other differences have caused FDA reviewers to be cautious about accepting data from outside the US, however they also realize this needs to be based on the risk of any differences.
As a result, clinical data from trials conducted in the UK or EU may not always be directly applicable or acceptable for FDA approval due to several factors related to the design, conduct, and population of the studies. Here are some aspects of the data that might lead to the need for additional trials or bridging studies.
Regulatory Standards and Guidelines
“Understanding the FDA’s expectations is critical. It’s not just about the data you present; it’s about presenting it in a way that aligns with the FDA’s unique framework. At QRx Partners, we help you translate your clinical trial results into the language of the FDA.”
Mark Swanson
Partner, QRx Partners
Clinical Trial Design
Data Quality and Integrity
Statistical Considerations
Ethical Standards
“The FDA’s approval process can be labyrinthine, with more nuances than many expect. Our experience at QRX shows that early and strategic engagement with the FDA can significantly streamline the approval journey for UK and EU companies.”
Steve Gompertz
Chief Operating Officer & Partner, QRx Partners
Bridging Studies
If the FDA determines that the data from UK or EU trials are not directly applicable to the U.S. population or do not meet FDA regulatory requirements, they may require “bridging studies.” Bridging studies are additional studies conducted to provide a link between the foreign clinical data and the U.S. population or to supplement the existing data to satisfy FDA-specific concerns. These studies might involve pharmacokinetic evaluations, limited clinical trials, or additional safety and efficacy data collection in a U.S. population.
FAQs: Navigating US Healthcare Regulations with UK/EU Clinical Data
Yes, UK or EU clinical trial data may be used as part of an FDA submission. However, the data must meet FDA standards, which can differ from EMA or MHRA requirements. Companies often need to conduct additional studies or provide supplementary information to ensure compliance with FDA regulations.
While there are many similarities, key differences include trial design, patient population, endpoints, and post-market safety reporting. The FDA may also require trials to be conducted under U.S. Investigational New Drug (IND) regulations.
Companies should engage with U.S. legal and regulatory experts familiar with FDA processes, consider strategic planning for regulatory submission, and maintain flexibility to adapt to the FDA’s feedback and changing guidelines.
Yes, challenges include aligning clinical trial data with FDA expectations, understanding federal vs. state laws, and keeping up with the constantly evolving regulatory landscape, particularly for digital health technologies.
If the FDA deems the data insufficient, the company may need to modify the trial protocol, collect additional data, or even start new clinical trials, leading to increased costs and delays in product approval.
Compliance with both federal and state regulations is essential to legally distribute products in the U.S. market. Discrepancies between these laws can affect marketing practices, pricing, insurance coverage, and distribution.
Non-compliance can result in financial penalties, legal action, product seizures, and damage to a company’s reputation. It can also significantly delay product approval or lead to market access restrictions.
Due to the complexity of U.S. regulations, it is often necessary to hire external experts who specialize in FDA law and practice to guide through the approval processes and ensure compliance.
Conclusion
In summary, the FDA has the responsibility to ensure that any product it approves is safe and effective for the U.S. population. Discrepancies in trial design, population, data collection, and regulatory standards may necessitate additional trials or bridging studies to meet FDA requirements.
Companies looking to gain FDA approval with non-U.S. clinical data should engage with the FDA early in the development process through pre-IND (Investigational New Drug) meetings and other consultations to understand the specific requirements and reduce the likelihood of costly additional studies.
Other Useful Resources
Disclaimer: The information provided in this article is for general informational purposes only and should not be construed as professional advice. Readers should not rely on any information contained herein as a substitute for professional guidance and should seek independent expert assistance when making decisions related to transfer pricing or US expansion.
